Core Insights - Arcadia Biosciences reported a 26% year-over-year increase in Zola coconut water revenues for the first nine months of 2025, despite flat revenues in the third quarter due to a comparison with a strong prior year [3][10][11] - The company achieved gross profit margins exceeding 30% for eleven consecutive quarters, with SG&A expenses at an all-time low [3][4] - Arcadia's cash balance slightly declined by $257,000 to $1.1 million, indicating effective cash management [3] Financial Performance - Total revenues for the third quarter of 2025 decreased by $235,000, or 15%, compared to the same period in 2024, primarily due to the absence of GLA oil sales [6][9] - For the first nine months of 2025, total revenues increased by $128,000, or 3%, driven entirely by Zola coconut water sales [6][10] - Operating expenses decreased by 26% in the third quarter and by 2% in the first nine months of 2025 compared to the same periods in 2024 [6][14] Net Income and Loss - Net income attributable to common stockholders for the third quarter of 2025 was $856,000, a significant improvement from a net loss of $1.6 million in the same quarter of 2024 [6][18] - The net loss attributable to common stockholders for the first nine months of 2025 was $1.0 million, improving from a loss of $3.0 million in the same period of 2024 [6][19] Business Developments - Arcadia continues to hold 2.7 million shares of Above Food Ingredients Inc. stock as part of a repayment related to the sale of GoodWheat assets [4][16] - The pending business combination with Roosevelt Resources is ongoing, but the timing remains uncertain due to external factors such as the federal government shutdown [5][20]